Platelet thromboxane (11-dehydro-Thromboxane B2) and aspirin response in patients with diabetes and coronary artery disease

Figure 8 Proposed schematic representation (algorithm) to guide the clinical interpretation and decision making process for assessing CVD risk using baseline (aspirin-free) urinary 11-dehydro-thromboxane B₂ (left), and post-aspirin 11-dehydro-thromboxane B₂ levels (right). Baseline 11-dehydro-thromboxane B2 levels suggested were taken from the mean and upper range of healthy controls. The cut-off of 1500 pg/mg applies only for subjects on aspirin (ASA) therapy to be classified as good or poor responders.